Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SSRIs And Suicide To Be Discussed By Pediatric Advisory Cmte. In September

This article was originally published in The Pink Sheet Daily

Executive Summary

Joint session with Psychopharmacologic Advisory Committee will be new cross-center committee's first meeting.

You may also be interested in...



FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14

Joint meeting of Psychopharmacologic and newly formed Pediatric Advisory Committees will review analysis performed by expert group assembled by Columbia University. Future research needs in pediatric suicidality will also be addressed.

FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14

Joint meeting of Psychopharmacologic and newly formed Pediatric Advisory Committees will review analysis performed by expert group assembled by Columbia University. Future research needs in pediatric suicidality will also be addressed.

FDA Forms Pediatric Ethics Subcommittee

The advisory panel will address pediatric ethical issues and IRB referrals related to clinical investigations involving children. The subcommittee's preliminary recommendations will be presented to the new Pediatric Advisory Committee.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS059726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel